WO1999002499A1 - Quinoline compounds and medicinal uses thereof - Google Patents
Quinoline compounds and medicinal uses thereof Download PDFInfo
- Publication number
- WO1999002499A1 WO1999002499A1 PCT/JP1998/003089 JP9803089W WO9902499A1 WO 1999002499 A1 WO1999002499 A1 WO 1999002499A1 JP 9803089 W JP9803089 W JP 9803089W WO 9902499 A1 WO9902499 A1 WO 9902499A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- heteroaryl
- pharmaceutically acceptable
- cycloalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020007000255A KR20010021696A (en) | 1997-07-11 | 1998-07-09 | Quinoline compounds and medicinal uses thereof |
AU81279/98A AU8127998A (en) | 1997-07-11 | 1998-07-09 | Quinoline compounds and medicinal uses thereof |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP20240097 | 1997-07-11 | ||
JP9/202400 | 1997-07-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999002499A1 true WO1999002499A1 (en) | 1999-01-21 |
Family
ID=16456881
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/003089 WO1999002499A1 (en) | 1997-07-11 | 1998-07-09 | Quinoline compounds and medicinal uses thereof |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR20010021696A (en) |
AU (1) | AU8127998A (en) |
WO (1) | WO1999002499A1 (en) |
Cited By (87)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000040562A1 (en) * | 1999-01-08 | 2000-07-13 | Japan Tobacco Inc. | 2-oxoquinoline compounds and medicinal uses thereof |
WO2000066260A1 (en) * | 1999-04-28 | 2000-11-09 | Toray Industries, Inc. | Materials for eliminating cannabinoids and columns for the elimination of cannabinoids with the use of the same |
WO2002053543A1 (en) | 2000-12-28 | 2002-07-11 | Shionogi & Co., Ltd. | Pyridone derivative having affinity for cannabinoid 2-type receptor |
WO2003061699A1 (en) * | 2001-12-27 | 2003-07-31 | Japan Tobacco, Inc. | Remedies for allergic diseases |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
WO2005007111A2 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
WO2005028438A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
JPWO2003070277A1 (en) * | 2002-02-19 | 2005-06-09 | 塩野義製薬株式会社 | Antipruritic agent |
US6916806B2 (en) | 2001-03-08 | 2005-07-12 | Shionogi & Co., Ltd. | Medicinal composition containing 1,3-thiazine derivative |
WO2005066126A1 (en) | 2003-12-23 | 2005-07-21 | Eli Lilly And Company | Cb1 modulator compounds |
WO2005097759A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
US6972295B2 (en) | 2002-03-12 | 2005-12-06 | Merck & Co., Inc. | Substituted amides |
WO2006017542A1 (en) | 2004-08-06 | 2006-02-16 | Merck & Co., Inc. | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
US7057051B2 (en) | 2001-07-20 | 2006-06-06 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7091216B2 (en) | 2002-08-02 | 2006-08-15 | Merck & Co., Inc. | Substituted furo[2,3-b]pyridine derivatives |
WO2006129826A1 (en) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
WO2007018248A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
WO2007024004A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2007049798A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
WO2007055418A1 (en) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
WO2008038692A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
WO2008060476A2 (en) | 2006-11-15 | 2008-05-22 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2008074384A1 (en) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
WO2008120653A1 (en) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
US7482339B2 (en) | 2003-08-26 | 2009-01-27 | Shionogi And Co., Ltd. | 2-Naphthylimino-1,3-thiazine derivative |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2009110510A1 (en) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Alkylaminopyridine derivative |
WO2009119726A1 (en) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
EP2127676A2 (en) | 2004-11-01 | 2009-12-02 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2009154132A1 (en) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Spirodiamine-diarylketoxime derivative |
WO2010013595A1 (en) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
US7728141B2 (en) | 2003-11-04 | 2010-06-01 | Merck Sharp & Dohme Corp. | Substituted naphthyridinone derivatives |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
WO2011058193A1 (en) | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
EP2330124A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
EP2330125A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US8071641B2 (en) | 2004-02-16 | 2011-12-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treating or preventing diabetes with cannabidiol |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
US8178681B2 (en) | 2004-10-28 | 2012-05-15 | Shionogi & Co., Ltd. | 3-carbamoyl-2-pyridone derivatives |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US8420689B2 (en) | 2005-06-02 | 2013-04-16 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
WO2013059222A1 (en) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
EP2698157A1 (en) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016030534A1 (en) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
US20210068444A1 (en) * | 2019-09-10 | 2021-03-11 | California Amber Inc. | Cannabinoid compositions with improved organoleptic and therapeutic properties, method of production, and use thereof |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2363459A1 (en) * | 1973-12-20 | 1975-06-26 | Basf Ag | 7-Amino-quinoline cpds. - for use as optical brighteners, dyes, colour formers in copying and in printing pastes |
JPH07252228A (en) * | 1994-02-07 | 1995-10-03 | Fujisawa Pharmaceut Co Ltd | Quinoline derivative |
-
1998
- 1998-07-09 KR KR1020007000255A patent/KR20010021696A/en not_active Application Discontinuation
- 1998-07-09 WO PCT/JP1998/003089 patent/WO1999002499A1/en not_active Application Discontinuation
- 1998-07-09 AU AU81279/98A patent/AU8127998A/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2363459A1 (en) * | 1973-12-20 | 1975-06-26 | Basf Ag | 7-Amino-quinoline cpds. - for use as optical brighteners, dyes, colour formers in copying and in printing pastes |
JPH07252228A (en) * | 1994-02-07 | 1995-10-03 | Fujisawa Pharmaceut Co Ltd | Quinoline derivative |
Non-Patent Citations (2)
Title |
---|
EL-KERDAWY M, ET AL.: "PREPARATION OF ALKOXYQUINOLINE DERIVATIVES AND THEIR EVALUATION AS POTENTIAL CENTRAL NERVOUS SYSTEM STIMULANTS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION., WASHINGTON, US, vol. 73, no. 11, 1 November 1984 (1984-11-01), WASHINGTON, US, pages 1652/1653, XP002917840, ISSN: 0022-3549, DOI: 10.1002/jps.2600731144 * |
VIJAYALAKSHMI S, RAJENDRAN S P: "SYNTHESIS OF DIBENZO¬B,HI1,6¾NAPHTHYRIDIN-6(5H)-ONES", INDIAN JOURNAL OF CHEMISTRY, JODHPUR, IN, vol. 33B, no. 02, 1 February 1994 (1994-02-01), IN, pages 159 - 162, XP002917841 * |
Cited By (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6806276B2 (en) | 1999-01-08 | 2004-10-19 | Japan Tobacco Inc. | 2-oxoquinoline compounds and pharmaceutical uses thereof |
WO2000040562A1 (en) * | 1999-01-08 | 2000-07-13 | Japan Tobacco Inc. | 2-oxoquinoline compounds and medicinal uses thereof |
US6509352B1 (en) | 1999-01-08 | 2003-01-21 | Japan Tobacco Inc. | 2-oxoquinoline compounds and medicinal uses thereof |
WO2000066260A1 (en) * | 1999-04-28 | 2000-11-09 | Toray Industries, Inc. | Materials for eliminating cannabinoids and columns for the elimination of cannabinoids with the use of the same |
US6531159B1 (en) | 1999-04-28 | 2003-03-11 | Toray Industries, Inc. | Materials eliminating cannabinoids and columns for the elimination of cannabinoids with the use of the same |
US8449908B2 (en) | 2000-12-22 | 2013-05-28 | Alltranz, Llc | Transdermal delivery of cannabidiol |
US8088924B2 (en) | 2000-12-28 | 2012-01-03 | Shionogi & Co., Ltd. | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
CN100575345C (en) * | 2000-12-28 | 2009-12-30 | 盐野义制药株式会社 | 2 type Cannabined receptors are had in conjunction with active Pyridione derivatives |
US7652141B2 (en) | 2000-12-28 | 2010-01-26 | Shionogi & Co., Ltd. | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor |
KR100828982B1 (en) * | 2000-12-28 | 2008-05-14 | 시오노기세이야쿠가부시키가이샤 | Pyridone derivative having affinity for cannabinoid 2-type receptor |
US6977266B2 (en) | 2000-12-28 | 2005-12-20 | Shionogi & Co., Ltd. | Pyridone derivatives having affinity for cannabinoid 2-type receptor |
WO2002053543A1 (en) | 2000-12-28 | 2002-07-11 | Shionogi & Co., Ltd. | Pyridone derivative having affinity for cannabinoid 2-type receptor |
US6916806B2 (en) | 2001-03-08 | 2005-07-12 | Shionogi & Co., Ltd. | Medicinal composition containing 1,3-thiazine derivative |
US7057051B2 (en) | 2001-07-20 | 2006-06-06 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7572785B2 (en) | 2001-07-20 | 2009-08-11 | Merck & Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
WO2003061699A1 (en) * | 2001-12-27 | 2003-07-31 | Japan Tobacco, Inc. | Remedies for allergic diseases |
EP2130820A1 (en) | 2002-02-19 | 2009-12-09 | Shionogi & Co., Ltd. | Antipruritics |
JPWO2003070277A1 (en) * | 2002-02-19 | 2005-06-09 | 塩野義製薬株式会社 | Antipruritic agent |
US7351729B2 (en) | 2002-03-08 | 2008-04-01 | Signal Pharmaceuticals, Llc | JNK inhibitors for use in combination therapy for treating or managing proliferative disorders and cancers |
US6972295B2 (en) | 2002-03-12 | 2005-12-06 | Merck & Co., Inc. | Substituted amides |
US7816534B2 (en) | 2002-03-12 | 2010-10-19 | Merck Sharp & Dohme Corp. | Substituted amides |
US7550489B2 (en) | 2002-03-12 | 2009-06-23 | Merck & Co., Inc. | Substituted pyridyoxy amides |
US7423067B2 (en) | 2002-03-26 | 2008-09-09 | Merck & Co., Inc. | Diphenyl cyclopentyl amides as cannabinoid-1 receptor inverse agonists |
US7271266B2 (en) | 2002-03-28 | 2007-09-18 | Merck & Co., Inc. | Substituted 2,3-diphenyl pyridines |
US7667053B2 (en) | 2002-04-12 | 2010-02-23 | Merck & Co., Inc. | Bicyclic amides |
US6825209B2 (en) | 2002-04-15 | 2004-11-30 | Research Triangle Institute | Compounds having unique CB1 receptor binding selectivity and methods for their production and use |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
US7091216B2 (en) | 2002-08-02 | 2006-08-15 | Merck & Co., Inc. | Substituted furo[2,3-b]pyridine derivatives |
US7884113B2 (en) | 2003-07-11 | 2011-02-08 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
WO2005007111A2 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US7276608B2 (en) | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
WO2005007628A1 (en) | 2003-07-11 | 2005-01-27 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US8119808B2 (en) | 2003-07-11 | 2012-02-21 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
US7482339B2 (en) | 2003-08-26 | 2009-01-27 | Shionogi And Co., Ltd. | 2-Naphthylimino-1,3-thiazine derivative |
WO2005028438A1 (en) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
US7728141B2 (en) | 2003-11-04 | 2010-06-01 | Merck Sharp & Dohme Corp. | Substituted naphthyridinone derivatives |
US7595339B2 (en) | 2003-12-23 | 2009-09-29 | Eli Lilly And Company | CB1 modulator compounds |
WO2005066126A1 (en) | 2003-12-23 | 2005-07-21 | Eli Lilly And Company | Cb1 modulator compounds |
US7276516B2 (en) | 2003-12-23 | 2007-10-02 | Eli Lilly And Company | CB1 antagonist compounds |
US8071641B2 (en) | 2004-02-16 | 2011-12-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Treating or preventing diabetes with cannabidiol |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2005097759A1 (en) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Diaryltriazoles as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2006017542A1 (en) | 2004-08-06 | 2006-02-16 | Merck & Co., Inc. | Sulfonyl compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase-1 |
US8178681B2 (en) | 2004-10-28 | 2012-05-15 | Shionogi & Co., Ltd. | 3-carbamoyl-2-pyridone derivatives |
US8367666B2 (en) | 2004-10-28 | 2013-02-05 | Shionogi & Co., Ltd. | 3-carbamoyl-2-pyridone derivatives |
EP2286837A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and obesity related diseases |
EP2286839A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related diseases |
EP2286840A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related diseases |
EP2127676A2 (en) | 2004-11-01 | 2009-12-02 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
EP2286838A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2006129826A1 (en) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | Novel piperidine derivative |
US8420689B2 (en) | 2005-06-02 | 2013-04-16 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
WO2007018248A1 (en) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Pyridone compound |
EP2330125A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
EP2330124A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
WO2007024004A1 (en) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Phenylpyridone derivative |
WO2007029847A1 (en) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Bicyclic aromatic substituted pyridone derivative |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
WO2007049798A1 (en) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Novel benzoxathiin derivative |
WO2007055418A1 (en) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Aza-substituted spiro derivative |
EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
EP2698157A1 (en) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
EP2946778A1 (en) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2008038692A1 (en) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Diaryl ketimine derivative |
WO2008060476A2 (en) | 2006-11-15 | 2008-05-22 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
WO2008074384A1 (en) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | 2-ADAMANTYL-BUTYRAMIDE DERIVATIVES AS SELECTIVE 11βETA-HSD1 INHIBITORS |
WO2008120653A1 (en) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Indoledione derivative |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009110510A1 (en) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Alkylaminopyridine derivative |
WO2009119726A1 (en) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | Diarylmethylamide derivative having antagonistic activity on melanin-concentrating hormone receptor |
WO2009127321A1 (en) | 2008-04-18 | 2009-10-22 | Merck Patent Gmbh, | Benzofurane, benzothiophene, benzothiazol derivatives as fxr modulators |
EP2110374A1 (en) | 2008-04-18 | 2009-10-21 | Merck Sante | Benzofurane, benzothiophene, benzothiazol derivatives as FXR modulators |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009154132A1 (en) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Spirodiamine-diarylketoxime derivative |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010013595A1 (en) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | (5-membered)-(5-membered) or (5-membered)-(6-membered) fused ring cycloalkylamine derivative |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010056717A1 (en) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Substituted bicyclic amines for the treatment of diabetes |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
WO2011011508A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Benzo-fused oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
WO2011011506A1 (en) | 2009-07-23 | 2011-01-27 | Schering Corporation | Spirocyclic oxazepine compounds as stearoyl-coenzyme a delta-9 desaturase inhibitors |
US8765728B2 (en) | 2009-11-16 | 2014-07-01 | Mellitech | [1,5]-diazocin derivatives |
WO2011058193A1 (en) | 2009-11-16 | 2011-05-19 | Mellitech | [1,5]-diazocin derivatives |
EP2923706A1 (en) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
US9340523B2 (en) | 2009-12-30 | 2016-05-17 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2011137024A1 (en) | 2010-04-26 | 2011-11-03 | Merck Sharp & Dohme Corp. | Novel spiropiperidine prolylcarboxypeptidase inhibitors |
WO2011143057A1 (en) | 2010-05-11 | 2011-11-17 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
WO2011156246A1 (en) | 2010-06-11 | 2011-12-15 | Merck Sharp & Dohme Corp. | Novel prolylcarboxypeptidase inhibitors |
EP3243385A1 (en) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2013059222A1 (en) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
US10513499B2 (en) | 2014-08-29 | 2019-12-24 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
US11254644B2 (en) | 2014-08-29 | 2022-02-22 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2016030534A1 (en) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
US20210068444A1 (en) * | 2019-09-10 | 2021-03-11 | California Amber Inc. | Cannabinoid compositions with improved organoleptic and therapeutic properties, method of production, and use thereof |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
KR20010021696A (en) | 2001-03-15 |
AU8127998A (en) | 1999-02-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1999002499A1 (en) | Quinoline compounds and medicinal uses thereof | |
JP2000256323A (en) | 2-oxoquinoline compound and its medicinal use | |
CN103649056B (en) | As the condensed heterocyclic compouds of ion channel modulators | |
CN101541751A (en) | Quinoline compounds | |
JP2003516391A (en) | Urea compounds having muscarinic receptor antagonist activity | |
KR20090122931A (en) | Ornithine derivative | |
CN106535901A (en) | A new class of mu-opioid receptor agonists | |
CZ292092A3 (en) | Tricyclic heterocyclic compounds | |
EP2119704A1 (en) | Acylguanidine derivative | |
CN102971327B (en) | There is the anti-inflammatory compound of multiple tyrosine-kinase enzyme inhibition activity and the pharmaceutical compositions containing these compounds | |
TW200304817A (en) | Chemical compounds | |
WO2004104000A1 (en) | Tricyclic condensed ring compound and medical use thereof | |
WO2022017515A1 (en) | Diarylamine compound, preparation method therefor and application thereof | |
JPH06503550A (en) | Quinoline derivatives, their production methods and uses | |
KR900006118B1 (en) | Process for preparing 4-quinolone derivatives | |
JPH1180124A (en) | Quinoline compound and its medicine use | |
TW474929B (en) | Sulfonamide-substituted chromans, processes for their preparation, their use as medicament or diagnostic aid, and medicament comprising them | |
WO2004103974A1 (en) | Substituted 2-oxoquinoline compound and medicinal use thereof | |
RU2314305C2 (en) | Derivatives of 4-(thio- or selenoxanthene-9-ylidene)-piperidine or acridine, pharmaceutical composition based on thereof and using | |
WO2012001120A1 (en) | Rupatadine salt as an antihistaminic agent | |
TW201607925A (en) | Morpholine compound | |
ES2234044T3 (en) | ANNULAR COMPOUNDS OF SEVEN MEMBERS, CONDENSED SUBSTITUTES WITH SULFONAMIDE WITH BLOCKING ACTIVITY OF THE POTASSIUM CHANNEL. | |
WO2004058772A1 (en) | Dihydrothienoquinoline derivatives and cell adhesion inhibitors containing the same | |
JPS62153280A (en) | 1,4-diazacycloalkane derivative | |
JP4317601B2 (en) | Sulfonamide-substituted compounds, their preparation, their use as pharmaceuticals or diagnostics and pharmaceutical formulations containing them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1020007000255 Country of ref document: KR |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1020007000255 Country of ref document: KR |
|
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 2000502027 Format of ref document f/p: F |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1020007000255 Country of ref document: KR |